BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 09, 2012
 |  BioCentury  |  Emerging Company Profile

JDP: Emergency antihistamines

JDP developing injectable antihistamine for acute allergies

JDP Therapeutics Inc. is hoping its injectable antihistamine can become standard of care for hospitalized patients suffering acute allergic reactions. By avoiding IV diphenhydramine's multiple doses and heavy sedative effects, the company is proposing its products will improve quality of care while producing cost savings for the healthcare system.

There are two main kinds of acute allergies: those suffered at home, such as reactions to nuts, shellfish or bee stings; and drug allergies, such as to penicillin.

Standard of care for acute allergies suffered at home is a self-administered intramuscular injection of epinephrine, followed by a trip to the emergency room, where patients receive IV diphenhydramine until their symptoms disappear.

Because diphenhydramine - better known by...

Read the full 563 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >